Fetal growth restriction remains one of the most challenging conditions in contemporary obstetric practice. When ultrasound examinations detect anomalous structural development alongside restricted growth, international guidelines routinely recommend invasive diagnostic evaluation. However, the diagnostic pathway for apparently isolated fetal growth restriction is far less straightforward. Clinicians often encounter substantial variation in clinical recommendations regarding gestational age cutoffs and diagnostic technology selection. Adopting a structured approach to genetic testing in FGR allows maternal-fetal medicine specialists to identify monogenic disorders and chromosomal abnormalities effectively while optimizing perinatal management.

Diagnostic Yield of Chromosomal Microarray in Growth Restriction

Chromosomal microarray analysis has superseded conventional G-banded karyotyping as the primary standard for invasive prenatal cytogenomic testing. In pregnancies complicated by growth restriction accompanied by structural anomalies, microarrays demonstrate pathogenic or likely pathogenic copy number variations in approximately 10% of cases. Conversely, establishing the exact diagnostic yield in isolated growth failure has historically proven difficult because published studies employ heterogeneous criteria. Furthermore, diagnostic definitions vary widely across international centers regarding growth percentiles and gestational age thresholds.

Recent pooled data demonstrate that chromosomal microarray provides an incremental diagnostic yield of approximately 3% over conventional karyotyping in isolated growth failure. Across rigorously defined isolated subgroups, pathogenic copy number variations appear in 0% to 8.1% of tested fetuses. Consequently, pre-test counseling must convey these realistic expectations to expectant parents. Clinicians should emphasize that while microarrays detect submicroscopic microdeletions and microduplications, a normal result does not completely exclude an underlying genetic etiology. Therefore, specialists must consider subsequent comprehensive molecular genomic evaluations when clinical suspicion remains elevated.

The Emerging Role of Exome Sequencing

When chromosomal microarray yields normal or uninformative results, prenatal exome sequencing provides substantial diagnostic utility. In fetal cohorts presenting with structural anomalies alongside growth restriction, exome sequencing achieves a diagnostic yield exceeding 30%. In contrast, among carefully selected cohorts presenting with apparently isolated growth failure, exome sequencing identifies causative monogenic variants in approximately 7% to 18% of cases. Thus, next-generation sequencing addresses a significant diagnostic gap for families seeking definitive answers.

However, clinicians must interpret current sequencing literature with caution. Many existing studies feature small sample sizes and variable inclusion criteria, which can inflate observed diagnostic yields. Moreover, sequencing inevitably uncovers variants of uncertain significance, introducing complex parental anxiety and counseling dilemmas. Pre-test and post-test genetic counseling therefore remains vital to ensure families understand potential diagnostic ambiguities. When specialists utilize exome sequencing judiciously, the molecular information obtained substantially refines recurrence risk estimates and improves neonatal management strategies.

Fetal Phenotypic Clues Informing Genetic Testing in FGR

Fetal sonographic phenotype represents the single strongest predictor of a positive molecular diagnosis. Specifically, fetuses exhibiting disproportionately shortened long bones demonstrate remarkably higher diagnostic yields on exome sequencing. These skeletal measurements often reflect underlying skeletal dysplasias, osteogenesis imperfecta, or distinct craniosynostosis syndromes rather than pure uteroplacental vascular dysfunction. Therefore, sonographers must scrutinize long bone biometry and skeletal morphology whenever estimated fetal weight drops below expected percentiles.

Additionally, clinicians should search meticulously for subtle dysmorphic markers that conventional screening might overlook. Minor facial dysmorphisms, persistent micrognathia, abnormal neurocranium contours, or subtle cardiac defects significantly elevate the pre-test probability of monogenic syndromes. Furthermore, longitudinal ultrasound assessments that document progressive skeletal discordance provide crucial diagnostic momentum. Recognizing these phenotypic nuances allows maternal-fetal medicine specialists to prioritize rapid genomic testing protocols over prolonged expectant observation.

Differentiating Placental Insufficiency from Genetic Etiologies

Distinguishing primary placental vascular insufficiency from an intrinsic genetic disorder is critical for clinical decision-making. Placental insufficiency typically manifests with characteristic hemodynamic alterations on Doppler velocimetry, including elevated umbilical artery pulsatility, absent or reversed end-diastolic velocity, and middle cerebral artery redistribution. In contrast, the conspicuous absence of maternal hypertensive disorders, abnormal uterine artery Doppler waveforms, or fetal hemodynamic compromise suggests a higher probability of an intrinsic genetic etiology.

Recently, circulating angiogenic biomarkers have emerged as valuable adjuncts in this diagnostic distinction. In particular, the maternal soluble fms-like tyrosine kinase-1 to placental growth factor ratio reflects systemic endothelial and trophoblastic dysfunction. While marked elevations in this ratio strongly correlate with placental-mediated growth restriction and preeclampsia, normal angiogenic biomarker concentrations point away from primary vascular pathology. Although using this biomarker profile to direct genomic testing remains hypothesis-generating, integrating angiogenic markers with Doppler parameters substantially refines patient selection for comprehensive sequencing.

A Structured Clinical Algorithm for Prenatal Practice

To deliver consistent care, maternal-fetal medicine units should implement a phenotype-driven diagnostic framework. First, clinicians must review prior first-trimester aneuploidy screening and cell-free DNA results to establish a baseline cytogenetic risk. Next, practitioners must perform a dedicated anatomical survey to rule out subtle structural dysmorphisms and skeletal discrepancies. If ultrasound identifies structural anomalies or severe early-onset growth failure before 24 weeks of gestation, teams should promptly offer invasive amniocentesis for chromosomal microarray analysis.

Furthermore, if chromosomal microarray analysis proves uninformative and the pregnancy lacks typical Doppler signs of placental insufficiency, teams should consider reflex exome sequencing. This systematic approach reduces unnecessary invasive testing in late-onset, mild vascular growth restriction while avoiding diagnostic delays in severe syndromic cases. Multidisciplinary collaboration among perinatologists, medical geneticists, and pediatric neonatologists ensures comprehensive post-test counseling, optimal delivery planning, and seamless transition to postnatal specialized care.

What is the diagnostic yield of chromosomal microarray in isolated FGR?

Chromosomal microarray analysis yields pathogenic or likely pathogenic findings in 0% to 8.1% of fetuses with isolated growth restriction. Furthermore, it provides an approximate 3% incremental diagnostic benefit over conventional G-banded karyotyping by identifying submicroscopic microdeletions and microduplications. In contrast, when growth restriction presents with coexisting structural anomalies, the diagnostic yield increases to approximately 10%, justifying prompt invasive cytogenomic investigation.

When should clinicians consider prenatal exome sequencing for growth restriction?

Clinicians should consider prenatal exome sequencing when chromosomal microarray testing is uninformative and structural abnormalities or disproportionate skeletal features coexist. In selected isolated cases, exome sequencing achieves a diagnostic yield between 7% and 18%, especially when clinical or Doppler evidence of placental insufficiency is entirely absent. Multidisciplinary genetic counseling must precede testing to address incidental findings and variants of uncertain significance.

How does maternal angiogenic biomarker testing assist in assessing growth restriction?

Maternal angiogenic biomarkers, particularly the sFlt-1 to PlGF ratio, reflect placental vascular health and trophoblastic dysfunction. A substantially elevated ratio strongly indicates placental-mediated growth restriction associated with vascular malperfusion. Conversely, completely normal biomarker concentrations in severe early-onset growth restriction suggest that placental insufficiency is unlikely, thereby increasing clinical suspicion for an underlying monogenic or syndromic genetic etiology.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Ashwal E et al. Genetic Investigation in Fetal Growth Restriction: An Integrated Approach for Clinical Practice. Prenat Diagn. 2026 Sep 25. doi: 10.1002/pd.70250. PMID: 42791229.
American College of Obstetricians and Gynecologists. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. Obstet Gynecol. 2021;137(2):e16-e28.
Melchiorre K et al. ISUOG Practice Guidelines: Diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020;56(2):298-312.